Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: An analysis of patients included in the CORAL study

Bone Marrow Transplantation

Volumn 52, Issue 2, 2017, Pages 216-221

  Van Den Neste, E ^a   Schmitz, N ^b   Mounier, N ^c   Gill, D ^d   Linch, D ^e   Trneny, M ^f   Bouadballah, R ^g   Radford, J ^h   Bargetzi, M ⁱ   Ribrag, V ^j   Duhrsen U ^k   Ma, D ^l   Briere, J ^m   Thieblemont, C ^m   Bachy, E ⁿ   Moskowitz, C H ^o   Glass, B ^b   Gisselbrecht, C ^m  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b DEPARTMENT OF CARDIOLOGY   (Germany)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f CHARLES UNIVERSITY   (Czech Republic)

^g INSTITUT PAOLI CALMETTES   (France)

^h CHRISTIE HOSPITAL   (United Kingdom)

ⁱ CANTONAL HOSPITAL AARAU   (Switzerland)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k UNIVERSITY HOSPITAL ESSEN   (Germany)

^l ST VINCENT S HOSPITAL   (Australia)

^m SAINT LOUIS HOSPITAL   (France)

ⁿ UNIVERSITÉ DE LYON   (France)

^o MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MELPHALAN; RITUXIMAB;

ADULT; AGE; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; DRUG RESPONSE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNATIONAL PROGNOSIS INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; WHOLE BODY RADIATION; ADOLESCENT; AUTOGRAFT; CLINICAL TRIAL; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE FREE SURVIVAL; FEMALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AUTOGRAFTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RECURRENCE; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

EID: 84988369353     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2016.213     Document Type: Article

References (23)

1. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184-4190.
2. Gisselbrecht C, Schmitz N, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012; 30: 4462-4469.
3. Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant 2015; 51: 51-57.
4. Nagle SJ, Woo K, Schuster SJ, Nasta SD, Stadtmauer E, Mick R et al. Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am J Hematol 2013; 88: 890-894.
5. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
6. Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29: 4079-4087.
7. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
8. Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 1992; 80: 2142-2148.
9. Robinson SP, Boumendil A, Finel H, Blaise D, Poire X, Nicolas-Virelizier E et al. Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party. Bone Marrow Transplant 2015; 51: 365-371.
10. Redondo AM, Pomares H, Vidal MJ, Pascual MJ, Quereda B, Sancho JM et al. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. Br J Haematol 2014; 164: 668-674.
11. van Kampen RJ, Canals C, Schouten HC, Nagler A, Thomson KJ, Vernant JP et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011; 29: 1342-1348.
12. Rigacci L, Puccini B, Dodero A, Iacopino P, Castagna L, Bramanti S et al. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol 2012; 91: 931-939.
13. Sirvent A, Dhedin N, Michallet M, Mounier N, Faucher C, Yakoub-Agha I et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 2010; 16: 78-85.
14. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR et al. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? Blood 2012; 120: 4256-4262.
15. Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. Ann Oncol 2008; 19: 1935-1940.
16. Glass B, Hasenkamp J, Wulf G, Dreger P, Pfreundschuh M, Gramatzki M et al. Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial. Lancet Oncol 2014; 15: 757-766.
17. Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA et al. Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. Bone Marrow Transplant 2015; 50: 1286-1292.
18. Kim JW, Kim SW, Tada K, Fukuda T, Lee JH, Lee JJ et al. Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. Ann Hematol 2014; 93: 1345-1351.
19. Avivi I, Canals C, Vernant JP, Wulf G, Nagler A, Hermine O et al. Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma. Bone Marrow Transplant 2014; 49: 671-678.
20. Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT et al. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol 2016; 174: 235-248.
21. Mondello P, Younes A. Emerging drugs for diffuse large B-cell lymphoma. Expert Rev Anticancer Ther 2015; 15: 439-451.
22. Nowakowski GS, Czuczman MS. ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection? Am Soc Clin Oncol Educ Book 2015; doi: 10.14694/EdBook-AM.2015.35.e449 e449-e457.
23. Camicia R, Winkler HC, Hassa PO. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer 2015; 14: 207.